Ben Bergo is CEO and co-founder of Visus Therapeutics. Ben is currently spearheading the development of Visus’ lead product, BRIMOCHOL™ PF, a prescription eye drop being studied to correct the loss of near vision associated with presbyopia. Driven by the company’s mission of offering patients a lifetime of clear vision, Ben recognizes the importance of a diverse portfolio. He is leading Visus in advancing its pipeline of early-stage ophthalmic drug candidates with applications in corneal wound healing, glaucoma, and age-related macular degeneration.

He has more than 20 years of experience in life sciences. Prior to Visus, he served as Executive Vice President of Corporate Development at Planet Innovation, where he led licensing and M&A transactions on behalf of the Planet Group. Additionally, he served as Co-founder and CEO at Nohla Therapeutics, Inc., a leader in the development of off-the-shelf cell therapies utilizing proprietary expanded cord blood formulations. Prior to this, he spun out technologies from Harvard University into a diagnostics venture that was later sold in 2015.

He received a Master’s in Applied Finance from Macquarie University as well as a Bachelor of Engineering and a Bachelor of Commerce in Economics and Finance, both from the University of Melbourne.